American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the first Phase 3 study to show a notable increase in event-free survival in the early stages of head and neck squamous cell carcinoma when using […]

The U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks Therapeutics, Inc.’s MEK inhibitor, for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company […]